Bone Marrow Transplantation (2010) 45, 1471–1473 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10
www.nature.com/bmt
LETTER TO THE EDITOR
Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions Bone Marrow Transplantation (2010) 45, 1471–1473; doi:10.1038/bmt.2009.369; published online 25 January 2010 Therapy-related myelodysplastic syndrome (t-MDS)/AML is a well-described complication of autologous BMT (auto-BMT), but it occurs rarely after allogeneic BMT. We report here a case of t-MDS/AML of recipient origin, associated with high-risk karyotypic abnormalities involving chromosome 7 that presented 1 year after allogeneic BMT for B-ALL and was successfully treated with donor lymphocyte infusions (DLIs). In February 2006, a 20-year-old man was diagnosed with pre-B ALL (CD34 þ , CD19 þ , CD22 þ , CD20, CD10 þ , Cm þ , sIg). The karyotype was hyperdiploid (55,XY, þ X, þ 4, þ 6, þ 14, þ 17, þ 18, þ 21x2, þ mar[5]/46, XY[15]). He was enrolled in the multicentric GRAALL 2003 trial and received induction therapy combining VCR, DNR, CY, L-asparaginase, prednisone and intrathecal chemotherapy. The patient was initially steroid- and chemotherapy resistant, but achieved complete haematological and cytogenetic remission after salvage chemotherapy. Unrelated HLA-B-mismatched BMT from a male donor was performed 7 months after diagnosis. The conditioning regimen consisted of high-dose CY, anti-thymoglobulin and 12 Gy fractionated TBI; GVHD prophylaxis consisted of CsA and short-course MTX. On day 23 post transplant, the patient developed grade II cutaneous and gastrointestinal GVHD that was successfully treated with steroids (2 mg/kg/ day). Immunosuppressive treatments were gradually tapered 6 months after BMT. Chimerism was 100% donor on day 30 and remained the same for 10 months after BMT. The patient then presented with neutropenia and thrombocytopenia (the ANC fell from 2.5 to 1 g/l and the plt count from 200 to 100 g/l). Concomitantly, analysis of blood chimerism showed 6% recipient cells, which increased to 27% 1 month later, with 40% of recipient cells in the CD3negative population. A BM aspirate revealed trilineage dysplasia with 4% blasts. The karyotype did not show the typical abnormalities found at diagnosis in leukaemia; however, the karyotype was complex, with three clones involving chromosome 7, as follows (see Figure 1): 46,XY,t(1;15)(p36;q21),del(7) (q31q35),t(12;16)(q21;p12)[5]/45,XY,t(2;21)(q12;q22),7, del(8)(p21),add(13)(q33),del(20)(q12q13)[5]/45,XY,add(3) (q24),7,10,add(19)(q13), þ mar[3]/ 46,XY[9]. According to the World Health Organization (WHO) classification, the diagnosis of ‘refractory anaemia with multilineage dysplasia and without excess of blasts’ was established. In addition, the presence of cytopenia and
complex chromosomal abnormalities made it an intermediate-2 (score ¼ 1.5) myelodysplasia, according to the International Prognostic Scoring System (IPSS) prognostic score. These findings were consistent with the diagnosis of t-MDS and the presence of monosomy 7 and t(2;21) (probably involving AML1 gene), suggesting alkylationinduced t-MDS.1 Considering the graft-vs-myelodysplasia effect, previously reported after nonmyeloablative transplant, and the known efficacy of DLI when administered for post transplant MDS relapse,2 the patient was treated with DLI, consisting of 1.5 107 CD3 þ cells/kg. He did not develop any sign of acute GVHD. At 6 weeks after DLI, he achieved CR, with normal blood cell counts, disappearance of haematological and karyotypic abnormalities on BM aspirate and complete donor chimerism (see Figures 2a and b). At 20 months after DLI, he was still in CR, but had limited chronic GVHD. Therapy-related myelodysplastic syndrome/AML is a frequent long-term complication of auto-BMT performed for both solid and haematological malignancies. The estimated incidence of t-MDS/AML after auto-BMT for lymphoma is between 1 and 14%, occurring from 3 to 15 years after auto-BMT.3 The pre auto-BMT chromosomal abnormalities seen in patients who go on developing t-MDS/AML support the hypothesis that stem cell damage is probably related to previous chemotherapy
1
2
3
6
7
8
13
14
15
19
20
9
10
16
21
22
4
5
11
12
17
18
X Y
Figure 1 Cytogenetic analysis (RHG banding techniques) performed in patient cells after allogenic BMT, showing one of the three identified clones with complex chromosomal abnormalities, comprising monosomy 7 (black arrow), compatible with the diagnosis of t-MDS/AML. RHG ¼ reverse banding using heat and Giemsa. 45,XY,t(2;21)(q12;q22),7,del(8)(p21), add(13)(q33),del(20)(q12q13)[5]. t(2;21) was confirmed using WCP21 probe (Kreatech, Strasbourg, France) (data not shown). In one of the other clones (data not shown), t(12;16)(q21;?p12) was confirmed using FISH probes (WCP15, WCP12, WCP16 (Kreatech) and D7S486(7q31)/CEP7 (Abbott, Rungis, France)).
Letter to the Editor
1472 DLI Abnormal Karyotype
% of host marker
100 10 Clinically relevant variation
1 0.1
Clinically non-relevant variation
0.01 0
2
4
6
8 10 12 14 16 18 20 22 24
Months post-transplant DLI
Platelets (G/L) ANC (G/L)
200
-3 - 2.5 -2 - 1.5 -1
150 100 50
ANC (G/L)
Platelets (G/L)
250
0 0
2
4
6 8 10 12 14 16 18 20 22 24 Months post-transplant
Figure 2
(a) Post transplant evolution of recipient chimerism in peripheral blood (represented in a log scale). This emphasizes the critical importance of performing chimerism studies to detect early any abnormal re-emergence of recipient haematopoietic cells. (b) Post transplant evolution of blood cell counts (plts, left y-axis; ANC, right y-axis).
rather than to the conditioning regimen administered before transplant.4 In contrast to what has been reported for auto-BMT, t-MDS/AML of recipient origin is a very rare occurrence after allogeneic BMT; among more than 8000 transplanted patients, only 6 cases have been reported in large retrospective studies evaluating long-term complications after allogeneic BMT.5 In the allogeneic setting, recipient haematopoietic destruction is achieved not only through the conditioning regimen but also with the assistance of the donor immune system, resulting most likely in risk reduction for the recipient. Nevertheless, t-MDS/AML frequency may be higher in transplants with a higher frequency of recipient stem cell survival, as seen with reduced-intensity conditioning transplant. Reappearance of recipient markers in chimerism analysis, concomitantly with the diagnosis of myelodysplastic syndrome, strongly suggests the recipient origin of this t-MDS/AML. It can be noted that the evolution of the blood counts, karyotype and BM aspiration was strictly correlated to that of recipient chimerism in peripheral blood, emphasizing the critical importance of performing chimerism studies to detect any abnormal reappearance of recipient haematopoietic cells early on. Therapy-related myelodysplastic syndrome/AML after auto-BMT carries a poor prognosis. The median survival time is o1 year, and is only 6 months when the karyotype is unfavourable.1,6 Usual treatment options consist of Bone Marrow Transplantation
supportive care, standard AML chemotherapy or allogeneic BMT,7 but such intensive therapies may lead to high toxicity in these already heavily treated patients. A previous case report showed that the rare occurrence of t-MDS/ AML after allogeneic BMT could be effectively treated by another allogeneic BMT from a different HLA-matched donor.8 Recently, the use of a nonmyeloablative conditioning regimen before allogeneic BMT or that of DLI for post transplant MDS relapse has shown promise of long-term remissions and suggests a graft-vs-myelodysplasia effect.2,9 In the case presented here, the successful treatment of t-MDS/AML with complex karyotype and poor prognosis using DLI alone also points to a strong graft-vs-myelodysplasia effect. Therapy-related myelodysplastic syndrome/AML of recipient origin is a very rare complication of allogeneic BMT; however, it may become more frequent with the recurrent use of nonmyeloablative conditioning regimens. Thus, chimerism analysis might be a useful tool for the early diagnosis of this complication, and early treatment with DLI may represent an effective and well-tolerated therapeutic option, although more case reports and more prolonged follow-ups are warranted.
Conflict of interest The authors declare no conflict of interest.
Letter to the Editor
1473
D Roos-Weil1, S Nguyen1, M Uzunov1, D Bories2, E Chapiro3, F Nguyen-Khac3, J-P Vernant1 and N Dhe´din1 1 Department of Haematology, Hoˆpital Pitie´-Salpeˆtrie`re, Paris, France; 2 Haematology Laboratory, Hoˆpital Henri Mondor, Cre´teil, France and 3 Cytogenetic Laboratory, Hoˆpital Pitie´-Salpeˆtrie`re, Paris, France E-mail:
[email protected]
4
5
6
7
References 1 Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43–52. 2 Campregher PV, Gooley T, Scott BL, Moravec C, Sandmaier B, Martin PJ et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40: 965–971. 3 Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia
8
9
in non-Hodgkin’s lymphoma patients. J Clin Oncol 2003; 21: 897–906. Abruzzese E, Radford JE, Miller JS, Vredenburgh JJ, Rao PN, Pettenati MJ et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 1999; 94: 1814–1819. Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1121–1134. Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22: 2510–2511. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35: 418–429. Au WY, Lie AK, Ma SK, Leung YH, Siu LL, Kwong YL. Therapy-related myelodysplastic syndrome of recipient origin after allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Br J Haematol 2001; 112: 424–426. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reducedintensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.
Bone Marrow Transplantation
